Andelyn Biosciences, a prominent player in the cell and gene therapy contract development and manufacturing organization (CDMO) landscape, has joined forces with ENCell Co., Ltd., a leading biopharmaceutical CDMO based in Korea. This collaboration aims to create a strategic manufacturing bridge between the United States and the Asia-Pacific (APAC) regions, significantly accelerating the global delivery of transformative gene therapies.
Accelerated Global Delivery
This partnership capitalizes on the cutting-edge GMP manufacturing facilities, technical expertise, and extensive networks of both companies. By streamlining the development, manufacturing, and expansion of client programs, they aim to bring next-generation gene therapies to patients around the world more efficiently.
Dual Hemisphere Workflow
One of the standout features of this collaboration is the implementation of a ‘dual hemisphere’ workflow. This model provides a direct connection between manufacturing hubs in the US and APAC, facilitating a simplified and cost-effective platform. By addressing regulatory and logistical challenges associated with international operations, the partnership ensures a smoother pathway for clinical trials and product commercialization.
Meeting Local Needs
A critical aspect of this partnership is its focus on regional supply chains. By enabling in-country manufacturing for local clinical trials, Andelyn and ENCell can better cater to the specific needs of patient populations in their respective regions. This approach not only reduces lead times but also enhances the overall accessibility of life-changing therapies.
Leadership Perspectives
Wade Macedone, CEO of Andelyn, emphasized the significance of this partnership, stating, “Our collaboration with ENCell is a powerful step forward in Andelyn’s mission to help bring life-saving therapies to patients worldwide.” He highlighted the mutual strengths that both companies bring to the table, reinforcing their commitment to creating a seamless international manufacturing network.
Dr. Jong Wook Chang, CEO of ENCell, echoed this sentiment, noting that their combined expertise in viral vector development and cGMP manufacturing will result in a more efficient and scalable production of gene therapies. This partnership, he stated, is pivotal for supporting clients from the initial stages of development through to global clinical trials and commercialization.
Enhancing Patient Access
This strategic alliance presents a significant opportunity to increase patient access to innovative gene therapies. By aligning their resources and expertise, Andelyn and ENCell can fulfill their mission to deliver more therapies to a broader patient base, enhancing the overall impact of gene therapy on global health.
Established Expertise
Andelyn Biosciences boasts over 20 years of experience in the field, specializing in the development, characterization, and production of viral vectors for gene therapy. The company has successfully produced cGMP material for more than 500 clinical batches and is involved in over 80 global clinical trials.
ENCell Co., Ltd., headquartered in Seoul, is a notable contributor to the advancement of cell and gene therapy development and manufacturing in Korea and across the APAC region. Together, these organizations are poised to make significant strides in the gene therapy sector.
Conclusion
The collaboration between Andelyn Biosciences and ENCell marks a transformative step in the gene therapy manufacturing landscape. With their combined capabilities, they are well-positioned to improve global access to innovative therapies, ultimately benefitting patients worldwide. This partnership not only strengthens their operational efficiencies but also sets a new standard for collaboration in the life sciences sector.
- Key Takeaways:
- The partnership aims to create a strategic manufacturing bridge between the US and APAC.
- A dual hemisphere workflow simplifies the international expansion of gene therapies.
- Local manufacturing for clinical trials enhances regional supply chains.
- Combined expertise increases efficiency in the development and production of therapies.
- The collaboration is expected to expand patient access to innovative gene therapies.
Read more → www.pharmabiz.com